2c 07

ZL0513 is a chromone derivatives used as orally bioavailable BRD4-selective inhibitor. This BRD4 BD1 inhibitor has demonstrated impressive in vivo efficacy and overall promising pharmacokinetic properties, indicating its therapeutic potential for the treatment of inflammatory diseases.

2C07 is a Novel switch-II binder. 2C07 alters nucleotide preference and inhibits SOS binding and catalyzed nucleotide exchange.